Biofrontera Inc. (BFRI) Shareholder/Analyst Call Prepared Remarks Transcript

WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or th

Wall Street analysts changed ratings on top names. Check our analyst ratings page for full updates.

Top Wall Street analysts upgraded STUB, PGNY, AMT, and BAP stocks and raised their price targets. Se

Benchmark analyst Bruce D. Jackson downgrades Biofrontera (NASDAQ:BFRI) from Buy to Speculative B

Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus

Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.41) per share which missed the analyst co

Woburn, MA, May 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (the "Company"), a biop

The second annual #HatsonforAK Campaign runs May 18–24, 2026, culminating on Global Actinic Keratosi

WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or th

Biofrontera (NASDAQ: BFRI) reported record revenue for both the fourth quarter and full year 2025, d

Biofrontera (NASDAQ:BFRI) reported quarterly earnings of $0.48 per share which beat the analyst cons

Biofrontera Inc. (BFRI) Q4 2025 Earnings Call Transcript

Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GL

WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or

Biofrontera Inc. (BFRI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abou

• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz ® PDT vers

Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization an

WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutica

RenovaCare (OTCMKTS:RCAR - Get Free Report) and Biofrontera (NASDAQ: BFRI - Get Free Report) are bot

WOBURN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or t

Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical

WOBURN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or t

Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutica

WOBURN, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or t

Biofrontera Inc. (NASDAQ: BFRI - Get Free Report)'s stock price traded down 5.6% during mid-day trad

Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a leader in photody

Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical

Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a leader in photod

Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3

sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on

Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.62) per share which missed the analyst co

Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of

Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch

All 172 patients have now entered the 12-month follow-up phaseTrial involves larger surface areas, b

Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026Compa